Editorial
Copyright ©2010 Baishideng.
World J Gastrointest Oncol. May 15, 2010; 2(5): 213-217
Published online May 15, 2010. doi: 10.4251/wjgo.v2.i5.213
Table 1 Relevant studies of PET in evaluating rectal cancer treatment response
StudynTherapyTimingResponse criteriaOutcome measureResultP
Engenhart et al[7] (1992)21RT8-9 wk pcΔSUVLCSUV normalization; PPV 20%; NPV 67%
Schiepers et al[14] (1999)9RT2-3 wk pcTuGlucHisto, cell kineticsDecreased 138 nmol/mL per min after RT0.008
Guillem et al[11] (2000)15CRT4-5 wk pcΔSUV, VR, δTLGHistoVR PPV 60%
Oku et al[9] (2002)40RT3-5 wk pcSUVRecurrenceSUV < 3.2< 0.05
Amthauer et al[15] (2004)20CRT + H2-4 wk pcΔSUVHisto36% decrease SUV PPV 93%; NPV 100%0.003
Calvo et al[16] (2004)25CRT4-5 wk pcΔSUVHisto2 vs 2.7 decrease SUVNS
Guillem et al[17] (2004)15CRT4-5 wk pcΔSUV, VR, δTLGRecurrence, OS, RFS63% decrease SUV 70% decrease TLG0.08 0.03
Denecke et al[18] (2005)23CRT + H2-4 wk pcΔSUVHisto36% decrease SUV PPV 77%; NPV 100%0.002
Konski et al[19] (2005)20CRT3-4 wk pcΔSUVHisto52% vs 75% decrease SUVNS
Cascini et al[20] (2006)33CRT12 d piΔSUVHisto22% vs 63% decrease SUV< 0.0001
Capirci et al[13] (2006)88CRT5-6 wk pcNegative PET5 yr OS and DFS91% vs 72% 81% vs 62% 0.024 0.003
Kalff et al[12] (2006)34CRT7-43 d pcVROS PFS100% vs 79% 100% vs 47%< 0.0001 < 0.0001
Capirci et al[21] (2007)45CRT5-6 wk pcΔSUVHisto66% decrease SUV PPV 77%; NPV 89%0.0015
Melton et al[22] (2007)21CRT4-5 wk pcΔSUV, VR, δTLGHisto70% decrease SUV PPV 58%; NPV 100%< 0.001
Kristiansen et al[23] (2008)30CRT7 wk pcVRHistoPPV 83%; NPV 33%NS
Siegel et al[8] (2008)32RT (short)7-8 d piΔSUVHisto40% decrease SUVNS
Nakagawa et al[10] (2008)59RT2-3 wk pcSUVOS MSSUV < 5: 95 vs 42 mo, 70% vs 44%0.042
Vliegen et al[24] (2008)20CRT4-6 wk pcΔSUVHisto83% vs 59% decrease SUV0.025
Janssen et al[25] (2009)30CRT2 wk pcΔSUVHisto43% decrease SUV PPV 91%; NPV 82%
Konski et al[26] (2009)53CRT3-4 wk pcΔSUVHisto67% vs 55% decrease SUVNS
Rosenberg et al[27] (2009)30CRTpcΔSUVHisto66% vs 48% decrease SUV PPV 83%; NPV 64%0.040